

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Technical Report Series

961

WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

Forty-fifth report



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

Forty-fifth report of the WHO Expert Committee on specifications for pharmaceutical preparations.

(WHO technical report series ; no. 961)

1. Pharmaceutical preparations — standards. 2. Technology, Pharmaceutical — standards.
3. Drug industry — legislation. 4. Quality control. I. World Health Organization. II. Series.

ISBN 978 92 4 120961 8

(NLM classification: QV 771)

ISSN 0512-3054

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

**Typeset in Switzerland
Printed in Switzerland**

Contents

1. Introduction	1
2. General policy	6
2.1 International collaboration	6
2.1.1 Collaboration with international organizations and agencies	6
European Directorate for the Quality of Medicines and HealthCare (Council of Europe)	6
The Global Fund to Fight AIDS, Tuberculosis and Malaria	6
United Nations Children's Fund	7
2.1.2 Pharmacopoeial Discussion Group	8
2.1.3 International Conference on Harmonisation	9
2.1.4 International Conference of Drug Regulatory Authorities	9
2.2 Cross-cutting issues in pharmaceuticals – quality assurance issues	10
2.2.1 Essential medicines	10
2.2.2 Herbal and complementary medicines	11
2.2.3 Regulatory support	12
3. Joint session with the Expert Committee on Biological Standardization	13
4. Quality control – specifications and tests	14
4.1 <i>The International Pharmacopoeia</i>	14
4.2 Current work plan and future work programme	15
4.3 Specifications for medicines, including children's medicines	16
4.3.1 Medicines for HIV and related conditions	16
4.3.2 Antimalarial medicines	16
4.3.3 Antituberculosis medicines	17
4.3.4 Anti-infectives	18
4.3.5 Other medicines	19
4.4 Revision of texts of <i>The International Pharmacopoeia</i>	19
4.4.1 Antimalarials: artesimnin derivatives	19
4.4.2 Other medicines	20
4.5 Review of published general monographs for dosage forms and associated method texts	21
4.5.1 Pharmacopoeial Discussion Group: harmonized general texts	21
4.5.2 Uniformity of content for single-dose preparations	23
4.6 General policy topics and general revision issues for <i>The International Pharmacopoeia</i>	24
4.6.1 Update on dissolution tests	24
4.6.2 Dry powders	25
5. Quality control – international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)	28
5.1 Update on transfer of International Chemical Reference Substances	28
5.2 Proposal for an accelerated release of International Chemical Reference Standards	29
5.3 Proposed first International Standard for biosynthetic human insulin	30

6. Quality control – national laboratories	31
6.1 External Quality Assurance Assessment Scheme	31
6.2 WHO good practices for pharmaceutical microbiology laboratories	32
7. Quality assurance – good manufacturing practices	33
7.1 Update of WHO good manufacturing practices: main principles for pharmaceutical products	33
7.2 WHO good manufacturing practices for blood establishments	33
7.3 Update of WHO good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms	34
7.4 Update of WHO good manufacturing practices: Water for pharmaceutical use	34
7.5 Revision of WHO good manufacturing practices: Sterile pharmaceutical products	35
8. Quality Assurance – new approaches	35
8.1 WHO guidelines on quality risk management	35
8.2 WHO guidelines on technology transfer	36
9. Quality assurance – distribution and trade of pharmaceuticals	36
9.1 Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services	36
9.2 Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products	38
9.3 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce	38
9.3.1 Update on current activities	38
9.3.2 Questions and answers	39
10. Prequalification of priority essential medicines	39
10.1 Update on the WHO Prequalification of Medicines Programme	39
10.2 Procedure for prequalification of pharmaceutical products	41
10.3 Guide on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities	41
11. Prequalification of quality control laboratories	41
11.1 Update of activities	41
11.2 Procedure for prequalifying laboratories	42
11.3 Update on the WHO guidelines for preparing a laboratory information file	43
12. Prequalification of active pharmaceutical ingredients	44
13. Regulatory guidance	44
13.1 WHO guidelines for preparing a site master file	44
13.2 Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format	45
13.3 Guidelines on submission of documentation for a multisource (generic) finished product: quality part	45

13.4	Pharmaceutical development for multisource (generic) pharmaceutical products	46
13.5	Classification of orally administered drugs on the WHO Model List of Essential Medicines according to the Biopharmaceutics Classification System	46
13.6	Development of paediatric medicines: pharmaceutical development	47
13.7	Quality requirements for artemisinin as a starting material in the production of antimalarial active pharmaceutical ingredients	47
14.	Nomenclature, terminology and databases	48
14.1	New definition for “substandard medicines”	48
14.2	“Spurious/false-labelled/falsified/counterfeit medicines”	49
14.3	International Nonproprietary Names (INN) for pharmaceutical substances	51
15.	Summary and recommendations	51
	Acknowledgements	58
	Annex 1	
	Release procedure of International Chemical Reference Substances	67
	Annex 2	
	WHO good practices for pharmaceutical microbiology laboratories	69
	Annex 3	
	WHO good manufacturing practices: main principles for pharmaceutical products	94
	Annex 4	
	WHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization)	148
	Annex 5	
	WHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms	215
	Annex 6	
	WHO good manufacturing practices for sterile pharmaceutical products	261
	Annex 7	
	WHO guidelines on transfer of technology in pharmaceutical manufacturing	285
	Annex 8	
	Good pharmacy practice: standards for quality of pharmacy services (joint FIP/WHO)	310
	Annex 9	
	Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products (jointly with the Expert Committee on Biological Standardization)	324
	Annex 10	
	Procedure for prequalification of pharmaceutical products	373

Annex 11	
Guidelines on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities	391
Annex 12	
Prequalification of quality control laboratories. Procedure for assessing the acceptability, in principle, of quality control laboratories for use by United Nations agencies	393
Annex 13	
WHO guidelines for preparing a laboratory information file	403
Annex 14	
WHO guidelines for drafting a site master file	409
Annex 15	
Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format	417

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Geneva, 18–22 October 2010

Members

Professor Ivan Addae-Mensah, Professor of Chemistry, University of Ghana, Legon, Ghana (*Chairperson*)

Professor Saleh A. Bawazir, Head of Drug Sector and Vice-President, Saudi Food and Drug Authority, Riyadh, Saudi Arabia (*Co-Chairperson*)

Mr Eshetu Wondemagegnehu Biwota, Addis Ababa, Ethiopia (*Co-Rapporteur*)

Mr Jean-Michel Caudron, Braine-le-Château, Belgium

Professor Theo G. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa

Ms Nilka M. Guerrero Rivas, Head of Quality Assurance, Instituto Especializado de Análisis, Ciudad Universitaria Octavio Méndez Pereira, Panamá, Republic of Panama

Professor Jos Hoogmartens, Professor Emeritus, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium

Professor Jin Shaohong,¹ Executive Deputy Director, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, People's Republic of China

Dr Toru Kawanishi, Head, Division of Drugs, National Institute of Health Sciences, Tokyo, Japan

Dr Justina A. Molzon, Associate Director for International Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA (*Co-Rapporteur*)

Professor Tamás L. Paál, President, Scientific Board, National Institute of Pharmacy, and Professor, University of Szeged, Budapest, Hungary

Temporary advisers

Dr Lucette Cargill, Director, Caribbean Regional Drug Testing Laboratory, Kingston, Jamaica

Mr Antonio Carlos da Costa Bezerra, Senior Pharmacist, Brazilian Health Surveillance Agency, Brasilia, Brazil

Professor Konstantin Keller, Director and Professor, Federal Ministry of Health, Bonn, Germany

Professor Henning G. Kristensen, Vedbaek, Denmark

Ms Gugu N. Mahlangu, Acting Director for Laboratory Services, Medicines Control Authority, Control Laboratory of Zimbabwe, Harare, Zimbabwe

¹ Unable to attend.

Ms Lynda Paleshnuik, Senior Quality Assessor, Val-des-Mont, QC, Canada

Ms Eija Pelkonen,² Head of Inspectorate, National Agency for Medicines, Helsinki, Finland

Ms Marie-Louise Rabouhans, Chiswick, London, England

Dr Jean-Louis Robert, Head, Official Medicines Control Laboratory, Service du Contrôle des Médicaments, Laboratoire National de Santé, Luxembourg

Dr Saranjit Singh, Professor and Head, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, SAS Nagar, India

Mr Deryck Smith, Principal Specialist, SSI, Cleanrooms Division, Guateng, South Africa

Dr Angelika Spreitzhofer,² AGES PharmMed GmbH, Vienna, Austria

Representation from United Nations offices³

United Nations Children's Fund (UNICEF)

Dr Peter Svarrer Jakobsen, Quality Assurance Officer, UNICEF Supply Division, Copenhagen, Denmark

Representation from specialized agencies and related organizations⁴

The Global Fund to Fight AIDS, Tuberculosis and Malaria

Ms Joelle Daviaud, Senior QA Technical Officer, Pharmaceutical Management Unit and Mr Raghu Kumar Krishna Swamy, Geneva, Switzerland

World Intellectual Property Organization (WIPO)

Ms Konji Sebati, Consultant, Department for Traditional Knowledge and Global Challenges

and Ms Maria Soledad Iglesias-Vega, Program Officer, Department of External Relations, Geneva, Switzerland

The World Bank

Dr Andreas Seiter, Senior Health Specialist — Pharmaceuticals, Health, Nutrition and Population, Washington, DC, USA

World Customs Organization (WCO)

Mr Alvaro Fernandez Acebes, Technical Officer, Tariff and Trade Affairs Directorate,

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28778

